Trial Profile
An interventional trial assessing the tolerability and safety of GRAZAX® in adults with grass pollen allergy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Mar 2014
Price :
$35
*
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Grass pollen hypersensitivity; Rhinoconjunctivitis; Seasonal allergic rhinitis
- Focus Adverse reactions
- Sponsors ALK-Abello
- 20 Mar 2014 New trial record